Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten research firms that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $24.30.
A number of equities analysts have commented on ALHC shares. UBS Group reissued a “neutral” rating on shares of Alignment Healthcare in a report on Wednesday, July 8th. Raymond James Financial set a $22.00 price target on Alignment Healthcare in a research note on Thursday, May 7th. Weiss Ratings raised Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. KeyCorp reiterated an “overweight” rating on shares of Alignment Healthcare in a research report on Wednesday, June 10th. Finally, Zacks Research downgraded Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th.
View Our Latest Analysis on ALHC
Alignment Healthcare Stock Performance
Alignment Healthcare (NASDAQ:ALHC – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. The firm had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.31 billion. Alignment Healthcare had a return on equity of 22.28% and a net margin of 0.89%.The company’s quarterly revenue was up 31.6% on a year-over-year basis. During the same period last year, the firm earned $0.07 EPS. On average, research analysts predict that Alignment Healthcare will post 0.2 earnings per share for the current year.
Insider Transactions at Alignment Healthcare
In other Alignment Healthcare news, insider Hyong Kim sold 35,951 shares of the company’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $19.86, for a total value of $713,986.86. Following the completion of the sale, the insider directly owned 331,750 shares in the company, valued at $6,588,555. This represents a 9.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John E. Kao sold 298,000 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $19.86, for a total value of $5,918,280.00. Following the completion of the sale, the chief executive officer directly owned 1,088,766 shares of the company’s stock, valued at $21,622,892.76. This trade represents a 21.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,039,951 shares of company stock valued at $19,976,967. 5.20% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Alignment Healthcare by 167.3% in the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock valued at $193,516,000 after purchasing an additional 6,940,277 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Alignment Healthcare by 232.5% during the 1st quarter. Bank of New York Mellon Corp now owns 3,313,110 shares of the company’s stock worth $58,377,000 after buying an additional 2,316,777 shares during the last quarter. Invesco Ltd. raised its position in shares of Alignment Healthcare by 122.3% during the 2nd quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock valued at $58,387,000 after buying an additional 2,294,739 shares during the period. Capital World Investors purchased a new stake in shares of Alignment Healthcare during the 4th quarter valued at approximately $44,203,000. Finally, Loomis Sayles & Co. L P purchased a new stake in shares of Alignment Healthcare during the 4th quarter valued at approximately $44,162,000. Institutional investors and hedge funds own 86.19% of the company’s stock.
Key Stories Impacting Alignment Healthcare
Here are the key news stories impacting Alignment Healthcare this week:
- Positive Sentiment: Q2 results exceeded expectations: Alignment reported adjusted earnings of $0.17 per share, above the $0.13 consensus estimate, while revenue of $1.34 billion surpassed estimates of $1.31 billion. Revenue increased 31.6% year over year, and net income more than doubled to $36.6 million as Medicare Advantage care costs improved. Alignment Healthcare Reports Second Quarter 2026 Results
- Positive Sentiment: Operating performance is improving: The company said it surpassed the high end of its guidance across key metrics, reflecting stronger membership growth, revenue, and profitability compared with the prior-year period. Alignment Healthcare Turns Profit
- Neutral Sentiment: Guidance remained broadly in line: Full-year 2026 revenue guidance was approximately $5.2 billion, and third-quarter revenue guidance was approximately $1.3 billion, generally matching analyst expectations. The lack of a material forecast increase may have limited the earnings-driven upside.
- Negative Sentiment: Several law firms announced investigations: Frank R. Cruz, Block & Leviton, Kaplan Fox, Lowey Dannenberg, and Pomerantz publicized inquiries into possible securities-law violations and alleged financial manipulation. The investigations follow an earlier sharp drop in ALHC shares and could create legal costs, reputational damage, and uncertainty regarding the company’s disclosures. The allegations have not been proven. Securities Fraud Investigation Into Alignment Healthcare
Alignment Healthcare Company Profile
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
Featured Stories
- Five stocks we like better than Alignment Healthcare
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
